Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

Similar articles for PubMed (Select 17846366)

1.

Burden and health care resource utilization in neovascular age-related macular degeneration: findings of a multicountry study.

Soubrane G, Cruess A, Lotery A, Pauleikhoff D, Monès J, Xu X, Zlateva G, Buggage R, Conlon J, Goss TF.

Arch Ophthalmol. 2007 Sep;125(9):1249-54.

PMID:
17846366
2.

Economic burden of bilateral neovascular age-related macular degeneration: multi-country observational study.

Cruess AF, Zlateva G, Xu X, Soubrane G, Pauleikhoff D, Lotery A, Mones J, Buggage R, Schaefer C, Knight T, Goss TF.

Pharmacoeconomics. 2008;26(1):57-73.

PMID:
18088159
4.

Burden of illness of neovascular age-related macular degeneration in Canada.

Cruess A, Zlateva G, Xu X, Rochon S.

Can J Ophthalmol. 2007 Dec;42(6):836-43.

PMID:
18026200
5.

[Neovascular age-related macular degeneration in Germany. Encroachment on the quality of life and the financial implications].

Pauleikhoff D, Scheider A, Wiedmann P, Gelisken F, Scholl HP, Roider I, Mohr A, Zlateva G, Xu X.

Ophthalmologe. 2009 Mar;106(3):242-51. doi: 10.1007/s00347-008-1797-9. German.

PMID:
18709375
6.

[Humanistic burden and health resource utilization among neovascular age-related macular degeneration patients in France].

Soubrane G, Zlateva G, Xu X, Buggage R, Kosa M.

J Fr Ophtalmol. 2008 Feb;31(2):138-45. French.

7.

Burden of illness of bilateral neovascular age-related macular degeneration in Spain.

Ruiz-Moreno JM, Coco RM, García-Arumí J, Xu X, Zlateva G.

Curr Med Res Opin. 2008 Jul;24(7):2103-11. doi: 10.1185/03007990802214300 . Epub 2008 Jun 10.

PMID:
18547463
8.

Investigating the burden of wet macular degeneration.

Mitchell J.

Arch Ophthalmol. 2007 Sep;125(9):1266-8. No abstract available.

PMID:
17846369
9.

Public health impact of neovascular age-related macular degeneration treatments extrapolated from visual acuity.

Bandello F, Lafuma A, Berdeaux G.

Invest Ophthalmol Vis Sci. 2007 Jan;48(1):96-103.

PMID:
17197522
10.

Health- and vision-related quality of life among patients with choroidal neovascularization secondary to age-related macular degeneration at enrollment in randomized trials of submacular surgery: SST report no. 4.

Dong LM, Childs AL, Mangione CM, Bass EB, Bressler NM, Hawkins BS, Marsh MJ, Miskala P, Jaffee HA, McCaffrey LA; Submacular Surgery Trials Research Group.

Am J Ophthalmol. 2004 Jul;138(1):91-108.

PMID:
15234287
11.

Cost-effectiveness of ranibizumab compared with pegaptanib in neovascular age-related macular degeneration.

Hernández-Pastor LJ, Ortega A, García-Layana A, Giráldez J.

Graefes Arch Clin Exp Ophthalmol. 2010 Apr;248(4):467-76. doi: 10.1007/s00417-009-1156-9. Epub 2009 Aug 11.

PMID:
19669678
12.

Computerized model of cost-utility analysis for treatment of age-related macular degeneration.

Fletcher EC, Lade RJ, Adewoyin T, Chong NV.

Ophthalmology. 2008 Dec;115(12):2192-8. doi: 10.1016/j.ophtha.2008.07.018. Epub 2008 Oct 18.

PMID:
18930556
13.

Depression, visual acuity, comorbidity, and disability associated with age-related macular degeneration.

Brody BL, Gamst AC, Williams RA, Smith AR, Lau PW, Dolnak D, Rapaport MH, Kaplan RM, Brown SI.

Ophthalmology. 2001 Oct;108(10):1893-900; discussion 1900-1.

PMID:
11581068
14.

The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis.

Wong TY, Chakravarthy U, Klein R, Mitchell P, Zlateva G, Buggage R, Fahrbach K, Probst C, Sledge I.

Ophthalmology. 2008 Jan;115(1):116-26. Epub 2007 Aug 6. Review. Erratum in: Ophthalmology. 2008 Sep;115(9):1524. Wong, Tien [corrected to Wong, Tien Y].

PMID:
17675159
15.

Vision-related quality of life in patients with bilateral severe age-related macular degeneration.

Cahill MT, Banks AD, Stinnett SS, Toth CA.

Ophthalmology. 2005 Jan;112(1):152-8.

PMID:
15629836
16.

Computer use among patients with age-related macular degeneration.

Brody BL, Field LC, Roch-Levecq AC, Depp C, Edland SD, Minasyan L, Brown SI.

Ophthalmic Epidemiol. 2012 Aug;19(4):190-5. doi: 10.3109/09286586.2012.672618.

PMID:
22775273
17.

Cost-effectiveness model for neovascular age-related macular degeneration: comparing early and late treatment with pegaptanib sodium based on visual acuity.

Javitt JC, Zlateva GP, Earnshaw SR, Pleil AM, Graham CN, Brogan AJ, Shah SN, Adamis AP.

Value Health. 2008 Jul-Aug;11(4):563-74. doi: 10.1111/j.1524-4733.2007.00283.x. Epub 2007 Dec 17.

PMID:
18179676
19.
20.

Delay in treating age-related macular degeneration in Spain is associated with progressive vision loss.

Arias L, Armadá F, Donate J, García-Arumí J, Giralt J, Pazos B, Piñero A, Martínez F, Mondéjar JJ, Ortega I, Zlateva G, Buggage R.

Eye (Lond). 2009 Feb;23(2):326-33. doi: 10.1038/sj.eye.6703053. Epub 2008 Jan 18.

PMID:
18202712
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk